Sign In
Buy CBIO
$17.98
+0.98 (+5.73%)
At Close: Jun 03, 2026
Catalyst Biosciences Appoints Charles Democko, Senior Vice President, Regulatory Affairs
12:00pm, Monday, 22'nd Jun 2020
Mr. Democko brings over 20 years of regulatory affairs experience in the development of both biologics and small molecules ranging from pre-IND through commercial stage companies across several therap
The oral presentation, entitled: “Combination of a Novel Chimeric AAV Capsid and Potency Enhanced FIX Variant for Hemophilia B Gene Therapy,” given by Dr. Grant Blouse, senior vice president of tr
Xconomy: Bio Roundup: A Royal IPO, Akili Arrives, Orca Bio Surfaces & More
03:33pm, Friday, 19'th Jun 2020
The biggest life sciences deal this week involves a company that doesn’t discover or develop drugs, or even sell them. Yet its mark is found on
Catalyst Biosciences Announces Pricing of Public Offering of Common Stock
01:00pm, Thursday, 18'th Jun 2020
Additionally, Catalyst has granted the underwriters a 30-day option to purchase up to an additional 692,307 shares of its common stock. All of the shares in the offering are being offered by Catalys
Catalyst Biosciences Announces Proposed Public Offering of Common Stock
08:01pm, Wednesday, 17'th Jun 2020
In addition, Catalyst expects to grant the underwriters of the offering a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the public offering. All
Hemophilia - Worldwide Markets, Pipeline, Epidemiology, Drugs, Sales, Shares and Forecasts to 2024 - ResearchAndMarkets.com
12:00am, Wednesday, 17'th Jun 2020
The
Catalyst Biosciences Appoints Clinton Musil as Chief Financial Officer
12:00pm, Monday, 15'th Jun 2020
“Mr. Musil brings a deep understanding of capital markets, financial strategy and M&A; experience to the Company and we are delighted to have him join Catalyst’s executive leadership team,” said
The poster, entitled: “Phase 2b Trial to evaluate the safety and factor IX levels of a daily subcutaneous prophylaxis treatment regimen of dalcinonacog alfa in Hemophilia B” presented by Howard Le
Connor Clark & Lunn Investment Management Ltd. Buys Shares of 63,992 Catalyst Biosciences Inc (NASDAQ:CBIO)
07:34am, Sunday, 14'th Jun 2020
Connor Clark & Lunn Investment Management Ltd. bought a new stake in Catalyst Biosciences Inc (NASDAQ:CBIO) during the 1st quarter, according to its most recent filing with the Securities and Exchange
The Week Ahead In Biotech: FDA Decisions In The Cards For Merck, Epizyme, Evoke And Ultragenyx
12:00am, Sunday, 14'th Jun 2020
Biotech stocks came under pressure along with the broader market in the week ended June 12, as a worsening pandemic situation and its impact on the economy led to an across-the-...
Aptose Biosciences (APTO) Receives a Buy from JonesTrading - Markets
02:51pm, Friday, 12'th Jun 2020
In a report released today, Matthew Cross from JonesTrading maintained a Buy rating on Aptose Biosciences (APTO – Research Report),
Catalyst Biosciences Present at the Raymond James Human Health Innovation Conference
12:00pm, Friday, 12'th Jun 2020
Catalyst is a research and clinical development biopharmaceutical company focused on addressing unmet needs in rare hematologic and systemic complement-mediated disorders. One of our key competitive
Catalyst Biosciences Completes MarzAA Pharmacokinetic & Pharmacodynamic Study
12:00pm, Wednesday, 10'th Jun 2020
The results support the use of SQ MarzAA to treat episodic bleeding. The company is on track to enroll the first patient in its Phase 3 registration trial evaluating the efficacy of SQ MarzAA to trea
Catalyst Biosciences Announces Oral and Poster Presentations at the World Federation of Hemophilia Virtual Summit 2020
12:00pm, Monday, 08'th Jun 2020
SOUTH SAN FRANCISCO, Calif., June 08, 2020 -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced oral and poster presentations at the upcoming World Foundation of.
Catalyst Biosciences Reports First Quarter 2020 Operating & Financial Results and Provides a Corporate Update
12:00pm, Monday, 11'th May 2020
MarzAA Phase 3 study first patient enrollment targeted before year end following FDA and EMA regulatory feedback DalcA Phase 2b study completed, final data to be presented in.
